ĐÁNH GIÁ HIỆU QUẢ ĐIỀU TRỊ VÀ TÁC DỤNG KHÔNG MUỐN CỦA PHÁC ĐỒ HOÁ XẠ TRỊ ĐỒNG THỜI TRIỆT CĂN VỚI CISPLATIN CHU KỲ 3 TUẦN TRONG UNG THƯ HẠ HỌNG - THANH QUẢN GIAI ĐOẠN III, IVA-B

Abstract

Objectives: To evaluate the response to combined chemotherapy and radiation therapy with cisplatin with a 3-week cycle for stage III, IVA-B hypopharyngeal - laryngeal cancer and its toxicity. Subjects and methods: A retrospective, prospective, and cross-sectional descriptive study on 32 patients with stage III, IVA-B laryngeal cancer who were initially treated with chemoradiotherapy and cisplatin with a 3-week cycle at the Department of Physics, radiation therapy - Military Medical Hospital 103 and the Department of Radiotherapy and Radiosurgery - 108 Central Military Hospital from January 2020 to October 2022. Results: 46.9% no clinical symptoms; 56.3% complete response; complete response in the tumor was 62.5%; complete response in lymph node was 56.3%. Undesirable effects of treatment on the hematopoietic system: Grade 4 BC lowering is 3.1%, and there is no case of grade 3 and 4 HGB lowering. Toxicity outside hematopoietic system in grade 3 and 4 includes dermatitis 62.5%; inflammation of the oral mucosa 65.6%; painful swallowing 3.1%. Conclusion: Simultaneous chemoradiotherapy with cisplatin for a 3-week cycle showed effective treatment for cancer of the pharynx - larynx stage III, IVA-B. Adverse effects are at an acceptable level.